InflaRx
Presence
InflaRx is a company listed under the stock ticker IFRX (DE).
Executives
View the org chart displaying its 25 main executives
Most searched biographies at InflaRx
- Niels Riedemann, Chief Executive Officer and Director
- Nicolas Fulpius, Chairman of the Board
- Richard Brudnick, Non-Executive Director
Popular executive movements at InflaRx
- Jan Medina has joined the company as Vice President and Head of Investor Relations (posted on February 23 2024).
Create your alert
to follow the executive moves at InflaRx.
Biotechnology
InflaRx has 2,297 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Johnson & Johnson has announced the acquisition of Proteologix (posted on May 20 2024).
- Rapport Therapeutics has just announced a $100 Million fundraising (posted on May 20 2024).
- Lycia Therapeutics has just announced a $107 Million fundraising (posted on May 15 2024).
Popular contacts in Biotechnology
News
Press releases by InflaRx
- 04-2024-InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
- 04-2024-InflaRx to Host Virtual R&D Event on June 5 and Report First Quarter 2024 Results on May 8
- 03-2024-InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
- 03-2024-InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
- 02-2024-InflaRx Appoints Jan Medina as Head of Investor Relations
- 01-2024-InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
- 01-2024-InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
- 11-2023-InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
- InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
- 09-2023-InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
- View more press releases Close
Social media about InflaRx
- InflaRx on Wikipedia, Google News & Yahoo Finance
- InflaRx on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Nicolas Fulpius 
